AUS
NZ
UK
CA
USA
IND
Headlines
- Breakthrough Study Results: Vaxcyte's stock surged over 36% after announcing positive results from a Phase I/II trial of its 31-valent pneumococcal conjugate vaccine, VAX-31. The vaccine demonstrated strong immune responses across multiple dose levels and showed potential advantages over Pfizer's Prevnar 20.
- Vaccine Performance Compared to Competitors: VAX-31 achieved high immune responses for 18 out of 20 common serotypes and outperformed Prevnar 20 in several key areas. Additionally, the vaccine's broader coverage aims to prevent over 95% of invasive pneumococcal diseases in older adults.
- Future Plans and Industry Context: Vaxcyte plans to advance VAX-31 to late-stage development and seeks regulatory approval by mid-2025. The company also has additional candidates in development and faces competition from Pfizer, Merck, and GSK in the pneumococcal vaccine market.
Shares of Vaxcyte (NASDAQ:PCVX) soared over 36% following the announcement of promising top-line results from a Phase I/II study of its investigational VAX-31, a 31-valent pneumococcal conjugate vaccine. This study, involving adults aged 50 and older, highlighted VAX-31’s robust immune responses across all dose levels.
The results revealed that VAX-31 met or exceeded regulatory immunogenicity criteria for most serotypes at the high and medium dose levels. The vaccine achieved immune responses comparable to, and in some cases surpassing, Pfizer’s Prevnar 20, which is the current benchmark in pneumococcal vaccination.
Comparison with Prevnar 20
The data demonstrated that VAX-31, at high and medium dose levels, generated stronger immune responses for several serotypes compared to Prevnar 20. Notably, VAX-31 showed higher responses for 18 of 20 serotypes at the high dose level and for 13 of 20 serotypes at the medium dose level. Additionally, VAX-31 met superiority criteria for the unique serotypes not included in Prevnar 20.
Stock Surge and Future Prospects
Following these positive results, Vaxcyte's stock reached an all-time high of $119.27. The company plans to advance VAX-31 to late-stage development, with a pivotal study expected to commence by mid-2025, pending regulatory approvals. Vaxcyte is also preparing to initiate a mid-stage study of VAX-31 for infants in early 2025.
In addition to VAX-31, Vaxcyte is developing another candidate, PCV-24, which is in Phase II trials for infants. Results from this study are anticipated by the end of the first quarter of 2025.
Competitive Landscape
The pneumococcal vaccine market is competitive, with Pfizer's Prevnar 13 and Prevnar 20, Merck's Vaxneuvance and Capvaxive, and GSK's 24-valent candidate, all vying for market share. Each of these vaccines targets multiple serotypes and addresses invasive pneumococcal disease, contributing to a dynamic and evolving industry landscape.
